Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.
Kaatz
G W
GW
Department of Internal Medicine, School of Medicine, Department of Veteran's Affairs Medical Center, Wayne State University, Detroit, Michigan 48201, USA. gkaatz@juno.com
Seo
S M
SM
Aeschlimann
J R
JR
Houlihan
H H
HH
Mercier
R C
RC
Rybak
M J
MJ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D006020:Glycopeptides; D007668:Kidney / Q000382:microbiology; D000077427:Lipoglycopeptides; D008297:Male; D016106:Methicillin Resistance; D011817:Rabbits; D013154:Spleen / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D014640:Vancomycin / Q000097:blood / Q000627:therapeutic use / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D014640:Vancomycin; C100708:oritavancin